NCT07221838 2026-03-03
OCTAGON
Alexion Pharmaceuticals, Inc.
Phase 4 Not yet recruiting
Clinical Trials
17 trialsNCT03016741 2026-02-24
Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer
Northwestern University
Phase 4 Active not recruiting
NCT07426484 2026-02-23
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
Dana-Farber Cancer Institute
Phase 4 Not yet recruiting
NCT05457257 2025-12-19
Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations
AstraZeneca
Phase 4 Completed
NCT03829371 2025-12-03
STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA
University of Turin, Italy
Phase 4 Active not recruiting
NCT06723548 2024-12-09
Telitacicept and Low-dose Steroids in Refractory Myasthenia Gravis
First Affiliated Hospital of Wenzhou Medical University
Phase 4 Not yet recruiting
NCT01995513 2023-09-18
PLATO
Pfizer
Phase 4 Completed
NCT04036721 2023-02-23
PROS-CONS
National Institute for Tuberculosis and Lung Diseases, Poland
Phase 4 Suspended
NCT02485691 2022-05-27
CARD
Sanofi
Phase 4 Completed
NCT00853008 2020-04-07
LAL-AR/2003
PETHEMA Foundation
Phase 4 Completed
NCT02773550 2020-01-18
Velcadito
Basque Health Service
Phase 4 Terminated
NCT01746992 2017-11-14
CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma
Ruijin Hospital
Phase 4 Unknown
NCT02074137 2016-06-02
Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer
Sanofi
Phase 4 Completed
NCT00526175 2016-01-20
LAL-BR/2001: Study Treatment to Low Risk ALL
PETHEMA Foundation
Phase 4 Completed
NCT01358253 2014-05-20
Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia
Ruijin Hospital
Phase 4 Completed
NCT00797810 2009-09-15
Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults
University of Bologna
Phase 4 Unknown
NCT00494897 2009-05-19
PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia
PETHEMA Foundation
Phase 4 Completed